[go: up one dir, main page]

PL3580211T3 - 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu - Google Patents

2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu

Info

Publication number
PL3580211T3
PL3580211T3 PL18703958T PL18703958T PL3580211T3 PL 3580211 T3 PL3580211 T3 PL 3580211T3 PL 18703958 T PL18703958 T PL 18703958T PL 18703958 T PL18703958 T PL 18703958T PL 3580211 T3 PL3580211 T3 PL 3580211T3
Authority
PL
Poland
Prior art keywords
dihydropyridazine
carboxamides
heteroaryl
oxo
cancer
Prior art date
Application number
PL18703958T
Other languages
English (en)
Inventor
Ilona GUTCHER
Ulrike RÖHN
Norbert Schmees
Ludwig Zorn
Lars RÖSE
Benjamin Bader
Christina KOBER
Rafael CARRETERO
Detlef STÖCKIGT
Horst Irlbacher
Michael Platten
Original Assignee
Bayer Aktiengesellschaft
Bayer Pharma Aktiengesellschaft
Deutsches Krebsforschungszentrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum filed Critical Bayer Aktiengesellschaft
Publication of PL3580211T3 publication Critical patent/PL3580211T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL18703958T 2017-02-09 2018-02-02 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu PL3580211T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17155406 2017-02-09
EP17202882 2017-11-21
EP18703958.1A EP3580211B1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL3580211T3 true PL3580211T3 (pl) 2021-04-19

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18703958T PL3580211T3 (pl) 2017-02-09 2018-02-02 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu

Country Status (38)

Country Link
US (2) US20240294505A1 (pl)
EP (1) EP3580211B1 (pl)
JP (1) JP7128826B2 (pl)
KR (1) KR102627266B1 (pl)
CN (3) CN110678459B (pl)
AU (1) AU2018217860B2 (pl)
BR (1) BR112019016497A2 (pl)
CA (1) CA3052718A1 (pl)
CL (1) CL2019002255A1 (pl)
CO (1) CO2019008684A2 (pl)
CR (1) CR20190364A (pl)
CU (1) CU24564B1 (pl)
CY (1) CY1124484T1 (pl)
DK (1) DK3580211T3 (pl)
DO (1) DOP2019000206A (pl)
EC (1) ECSP19057713A (pl)
ES (1) ES2847162T3 (pl)
GE (1) GEP20217281B (pl)
HR (1) HRP20210143T1 (pl)
HU (1) HUE053191T2 (pl)
IL (1) IL268469B (pl)
JO (1) JOP20190193A1 (pl)
LT (1) LT3580211T (pl)
MA (1) MA47447B1 (pl)
MX (1) MX2019009571A (pl)
NI (1) NI201900085A (pl)
PE (1) PE20191496A1 (pl)
PH (1) PH12019501846A1 (pl)
PL (1) PL3580211T3 (pl)
RS (1) RS61401B1 (pl)
SA (1) SA519402422B1 (pl)
SG (1) SG11201907232XA (pl)
SI (1) SI3580211T1 (pl)
TW (1) TWI770113B (pl)
UA (1) UA124507C2 (pl)
UY (1) UY37606A (pl)
WO (1) WO2018146010A1 (pl)
ZA (1) ZA201905902B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
BR112022007837A2 (pt) 2019-12-16 2022-07-05 Bayer Ag Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
EP4126839A4 (en) * 2020-03-27 2024-04-17 Dong-A ST Co., Ltd. AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221A (zh) * 2020-11-27 2022-05-27 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
AU2022345008A1 (en) * 2021-09-14 2024-04-04 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders
EP4419685A1 (en) 2021-10-20 2024-08-28 University of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
EP1130015A4 (en) * 1998-08-14 2006-02-08 Nihon Nohyaku Co Ltd PYRIDAZINONE DERIVATIVES
IL154709A0 (en) 2000-09-18 2003-10-31 Eisai Co Ltd Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
AU2007336781C1 (en) * 2006-12-21 2014-10-09 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
BR112013002079B1 (pt) 2010-07-27 2021-09-14 Trustees Of Boston University Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
WO2015143164A1 (en) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods
KR20190009369A (ko) * 2016-05-25 2019-01-28 바이엘 파마 악티엔게젤샤프트 3-옥소-2,6-디페닐-2,3-디히드로피리다진-4-카르복스아미드
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CA3082856A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

Also Published As

Publication number Publication date
CL2019002255A1 (es) 2020-01-03
EP3580211B1 (en) 2020-12-02
EP3580211A1 (en) 2019-12-18
CA3052718A1 (en) 2018-08-16
ZA201905902B (en) 2021-05-26
JP2020506946A (ja) 2020-03-05
US11795164B2 (en) 2023-10-24
UY37606A (es) 2018-09-28
MX2019009571A (es) 2020-01-20
JOP20190193A1 (ar) 2019-08-08
IL268469B (en) 2022-04-01
HUE053191T2 (hu) 2021-06-28
GEP20217281B (en) 2021-08-10
AU2018217860B2 (en) 2021-07-08
DK3580211T3 (da) 2021-01-25
CR20190364A (es) 2019-09-27
PE20191496A1 (es) 2019-10-21
AU2018217860A1 (en) 2019-08-22
US20230121195A1 (en) 2023-04-20
CO2019008684A2 (es) 2019-08-20
IL268469A (en) 2019-09-26
UA124507C2 (uk) 2021-09-29
NI201900085A (es) 2019-11-15
CY1124484T1 (el) 2022-07-22
TW201840549A (zh) 2018-11-16
MA47447A (fr) 2019-12-18
KR20190115460A (ko) 2019-10-11
US20240294505A1 (en) 2024-09-05
KR102627266B1 (ko) 2024-01-24
CN116531380A (zh) 2023-08-04
JP7128826B2 (ja) 2022-08-31
RS61401B1 (sr) 2021-02-26
ECSP19057713A (es) 2019-08-30
WO2018146010A1 (en) 2018-08-16
MA47447B1 (fr) 2021-02-26
CN116554152A (zh) 2023-08-08
ES2847162T3 (es) 2021-08-02
TWI770113B (zh) 2022-07-11
LT3580211T (lt) 2021-02-25
SA519402422B1 (ar) 2021-11-14
CU20190073A7 (es) 2020-03-04
SI3580211T1 (sl) 2021-06-30
CU24564B1 (es) 2022-01-13
CN110678459A (zh) 2020-01-10
PH12019501846A1 (en) 2020-03-09
SG11201907232XA (en) 2019-09-27
BR112019016497A2 (pt) 2022-05-10
CN110678459B (zh) 2023-04-04
DOP2019000206A (es) 2019-09-30
HRP20210143T1 (hr) 2021-03-19

Similar Documents

Publication Publication Date Title
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1247202A1 (zh) 用於治療癌症的化合物
HK1247129A1 (zh) 治療癌症的聯合療法
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL259996A (en) Combinations for cancer treatment
PT3576740T (pt) Tratamento de cancro
IL299099B1 (en) Combinations of cancer treatments
GB201706451D0 (en) Cancer treatment
IL268463A (en) Cancer treatment
EP3490561A4 (en) COMBINATIONS FOR THE TREATMENT OF CANCER
EP3503887A4 (en) COMBINATIONS FOR TREATING CANCER
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL274626A (en) Cancer treatment
HK1251794A1 (zh) 癌症治療
GB201707864D0 (en) Platinum-reistant cancer treatment
IL273835A (en) Combined product for cancer treatment
GB201819920D0 (en) Cancer treatment
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL253642A0 (en) Combined treatment for cancer
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB201811431D0 (en) Cancer treatment
GB201713852D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer